Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1649 1658 1675
This examiner grants 34% of resolved cases
Chang Yu Wang is an examiner in Art Unit 1643 within Tech Center 1600. The examiner has handled 872 resolved cases with an allowance rate pct of 33.5. This low rate indicates a challenging environment for patent applicants in the biotechnology sector.
The interview lift pct of 53.5 is a critical metric for this examiner. It suggests that despite the low 33.5% allowance rate, interviews can dramatically improve the chances of success. This high lift highlights the importance of verbal advocacy in this unit.
The median days to allowance is 1421. This long duration reflects the complexity of cases in Tech Center 1600. With 872 resolved cases, the data provides a comprehensive look at the examiner's rigorous standards and the potential for interviews to mitigate them.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17762543 | VACCINE THERAPY FOR RAN PROTEIN DISEASES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18455205 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | Non-Final OA | Iowa State University Research Foundation, Inc. |
| 17304444 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | Non-Final OA | Iowa State University Research Foundation, Inc. |
| 17790340 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | Final Rejection | Ohio State Innovation Foundation |
| 17883072 | Anti-CGRP Antibody Formulation | Non-Final OA | Eli Lilly and Company |
| 17801776 | METHODS OF USE OF ANTI-TREM2 ANTIBODIES | Non-Final OA | Washington University |
| 17816067 | AMELIORATION AND TREATMENT OF BRAIN DISORDER RESULTING FROM FETAL GROWTH RETARDATION USING PLURIPOTENT STEM CELLS | Non-Final OA | TOHOKU UNIVERSITY |
| 18560791 | CHIMERIC ANTIGEN RECEPTOR TO TARGET HLA-G-POSITIVE CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | Final Rejection | NOVARTIS AG |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | Final Rejection | Novartis AG |
| 18636898 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF HEMORRHAGIC STROKE | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 17793355 | CHIMERIC ANTIGEN RECEPTORS FOR REMOVAL OF AMYLOID | Non-Final OA | University of Tennessee Research Foundation |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | Non-Final OA | Janssen Pharmaceutica NV |
| 17437968 | METHOD FOR SCREENING COMPOUND FOR TREATING OR PREVENTING POLYQ-RELATED NEURODEGENERATIVE DISEASES | Non-Final OA | FUDAN UNIVERSITY |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | Non-Final OA | Viela Bio, Inc. |
| 17261480 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY (HAM), AND METHOD FOR TREATING HAM | Non-Final OA | ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy